|Bid||51.50 x 1800|
|Ask||51.75 x 1400|
|Day's Range||48.25 - 51.79|
|52 Week Range||44.76 - 168.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tesaro (TSRO) generated total revenues of $49.7 million in the first quarter—compared to $3 million in the first quarter of 2017. Tesaro’s licensing and collaboration revenues were $934,000 in the first quarter of 2017. The change was due to a $1 million reversal of milestone payments recognized by Tesaro in 2015 and 2016 from the Hengrui license agreement. Tesaro concluded that the agreement probably wouldn’t be achieved.
Tesaro used $147.6 million in operating activities in the first quarter—compared to $114.6 million in the first quarter of 2017. The company used $1.6 million in investing activities in the first quarter—compared to $1.8 million in the first quarter of 2017. The expense was mainly for purchasing property and equipment related to Tesaro expanding leased premises at its headquarters.
Tesaro’s (TSRO) products on the market are Zejula and Varubi. Zejula has been approved in the United States and the European Union as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Varubi has been approved in the United States and the European Union in combination with other antiemetic agents in adults to prevent delayed nausea and vomiting associated with chemotherapy.
Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. Tesaro’s insiders have invested 150,532 shares in theRead More...
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza. In 1Q18, Merck reported $33 million as its share of the Lynparza alliance revenues, of which $24 million were earned in US markets, while the remaining $9.0 million were reported from international markets. Lynparza is currently the leading PARP inhibitor in terms of new and total prescriptions for its approved label in ovarian cancer and breast cancer indications.
Considered a year ago to be among the top takeover targets in biotech, Tesaro Inc. and Clovis Oncology Inc. have so far failed to live up to their hype on Wall Street. Shares of Tesaro have fallen 71 percent since the U.S. Food and Drug Administration approved its ovarian cancer drug Zejula in March 2017. Clovis is down 32 percent over that time as its competing therapy has also struggled to meet sales estimates.
When Tesaro Inc (NASDAQ:TSRO) released its most recent earnings update (31 March 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
Tesaro on Thursday reported a loss of $2.98 per share on $49.7 million in revenue for its first quarter.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $2.98. The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
Tesaro popped Monday after unveiling early data for a potential competitor to drugs from Dow Jones component Merck and Bristol.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last month, ETFs holding TSRO are favorable, with net inflows of $5.12 billion.
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Eclipse Resources Corp (NYSE: ECR ) stock was trading ...
CEO of Tesaro Inc (NASDAQ:TSRO) Leon O Jr Moulder bought 5,000 shares of TSRO on 03/02/2018 at an average price of $56.93 a share.